Form 4: Indivior Director Granted 3,722 Restricted Stock Units

Indivior Pharmaceuticals Director Mark Stejbach received a grant of 3,722 Restricted Stock Units, increasing his beneficial ownership to 20,569 shares.

Summary

• Mark Stejbach, a Director of Indivior Pharmaceuticals, Inc. (INDV), was granted 3,722 Restricted Stock Units (RSUs) on January 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, contingent on Mr. Stejbach's continued service.
• Following this transaction, Mr. Stejbach beneficially owns a total of 20,569 shares of Indivior Pharmaceuticals common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects a routine compensation event that aligns director interests with shareholders, indicating continued commitment and standard corporate governance practices.

Positives

• The grant of Restricted Stock Units to a Director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The increase in beneficial ownership demonstrates continued commitment from a key board member.

Future Outlook

The granted Restricted Stock Units are subject to future vesting, which will occur on the day immediately preceding the first annual meeting of stockholders following the grant date, provided the Director maintains continued service to the Issuer.

Industry Context

The grant of Restricted Stock Units is a standard practice in executive and director compensation across various industries, including pharmaceuticals, to incentivize long-term performance and align the interests of leadership with shareholders.

Comparison to Industry Standards

• Equity-based compensation, such as RSU grants, is a common component of director remuneration in publicly traded companies, comparable to practices at peers like Johnson & Johnson or Pfizer, which also utilize stock awards to retain and motivate their board members.
• The vesting schedule tied to continued service is a typical mechanism to ensure long-term commitment and performance from directors, consistent with corporate governance best practices observed globally.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Director's financial interests with shareholder value creation, potentially leading to more focused decision-making for long-term growth.
• Employees: While not directly impacting employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The Restricted Stock Units will vest on the day immediately preceding the first annual meeting of the Issuer's stockholders following the grant date, subject to continued service.

Key Dates

Keywords

Indivior Pharmaceuticals, INDV, Restricted Stock Units, RSU grant, insider transaction, director compensation, beneficial ownership, equity compensation